Literature DB >> 566216

Immunomodulating effects in vitro of a hydroxythiazolobenzimidazole in the absence of mitogenicity.

G H Warren, L Mills, H Friedman.   

Abstract

Wy-13, 876, a hydroxythiazolobenzimidazole, enhanced in vitro antibody formation by mouse spleen cells immunized with sheep red blood cells. The optimal dose was 25--50 microgram/culture. The compound did not have a mitogenic effect at any dose.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 566216     DOI： 10.1007/bf01947337

Source DB:  PubMed          Journal:  Experientia        ISSN： 0014-4754


  5 in total

1.  Editorial: Immune activation of B cells: evidence for 'one nonspecific triggering signal' not delivered by the Ig receptors.

Authors:  A Coutinho; G Möller
Journal:  Scand J Immunol       Date:  1974       Impact factor: 3.487

2.  Immunosuppression induced in vitro by mastocytoma tumor cells and cell-free extracts.

Authors:  I Kamo; C Patel; J Kateley; H Friedman
Journal:  J Immunol       Date:  1975-06       Impact factor: 5.422

3.  Anti-tumour and anti-metastatic activity of 3-(P-Chlorophenyl)-2,3-Dihydro-3-Hydroxythiazolo (3,2-A)-Benzimidazole-2-acetic acid (WY-13,876).

Authors:  R L Fenichel; F J Gregory; H E Alburn
Journal:  Br J Cancer       Date:  1976-03       Impact factor: 7.640

4.  The mitogenic effect of lipopolysaccharide on bone marrow-derived mouse lymphocytes. Lipid A as the mitogenic part of the molecule.

Authors:  J Andersson; F Melchers; C Galanos; O Lüderitz
Journal:  J Exp Med       Date:  1973-04-01       Impact factor: 14.307

5.  The use of bacterial lipopolysaccharides to show that two signals are required for the induction of antibody synthesis.

Authors:  J Watson; E Trenkner; M Cohn
Journal:  J Exp Med       Date:  1973-09-01       Impact factor: 14.307
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.